Feline immunodeficiency virus and retrovirus-mediated adventitial ex vivo gene transfer to rabbit carotid artery using autologous vascular smooth muscle cells

Journal of Molecular and Cellular Cardiology

Volumn 36, Issue 3, 2004, Pages 333-341

  Kankkonen, Hanna M ^a   Turunen, Mikko P ^a   Hiltunen, Mikko O ^a   Lehtolainen, Pauliina ^a   Koponen, Jonna ^a   Leppänen, Pia ^a   Turunen, Anna Mari ^a   Ylä Herttuala, Seppo ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Galactosidase; Apolipoprotein E; Arterial wall; Lentivirus; VSV G; WHHL rabbit

Indexed keywords

APOLIPOPROTEIN E3; BETA GALACTOSIDASE; COLLAGEN; LOW DENSITY LIPOPROTEIN RECEPTOR; THROMBOSPONDIN; VIRUS VECTOR;

ANIMAL CELL; ARTERY WALL; ARTICLE; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; EAR ARTERY; FELINE IMMUNODEFICIENCY VIRUS; GENE EXPRESSION; GENE TRANSFER; HYPERLIPIDEMIA; MARKER GENE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RETROVIRUS; SMOOTH MUSCLE FIBER; TRANSGENE; VASCULAR SMOOTH MUSCLE; VESICULAR STOMATITIS VIRUS;

ANIMALS; APOLIPOPROTEIN E3; APOLIPOPROTEINS E; BETA-GALACTOSIDASE; CAROTID ARTERIES; CATS; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNODEFICIENCY VIRUS, FELINE; MEMBRANE GLYCOPROTEINS; MYOCYTES, SMOOTH MUSCLE; RABBITS; TRANSDUCTION, GENETIC; TRANSPLANTATION, AUTOLOGOUS; VASCULAR DISEASES; VASCULAR SURGICAL PROCEDURES; VIRAL ENVELOPE PROTEINS;

FELIDAE; FELINE IMMUNODEFICIENCY VIRUS; LENTIVIRUS; ORYCTOLAGUS CUNICULUS; UNIDENTIFIED RETROVIRUS; VESICULAR STOMATITIS VIRUS;

EID: 1542268967     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2003.11.011     Document Type: Article

References (47)

1. Laitinen M., Ylä-Herttuala S. Adventitial gene transfer to arterial wall. Pharmacol Res. 37:1998;251-254.
2. Lombardi J.V., Naji M., Larson R.A., Ryan S.V., Naji A., Koeberlein B., et al. Adenoviral mediated uteroglobin gene transfer to the adventitia reduces arterial intimal hyperplasia. J Surg Res. 99:2001;377-380.
3. Armeanu S., Haessler I., Saller R., Engelmann M.G., Heinemann F., Krausz E., et al. In vivo perivascular implantation of encapsulated packaging cells for prolonged retroviral gene transfer. J Microencapsul. 18:2001;491-506.
4. Ylä-Herttuala S., Alitalo K. Gene transfer as a tool to induce therapeutic vascular growth. Nat Med. 9:2003;694-701.
5. Akyurek L.M., Yang Z.Y., Aoki K., San H., Nabel G.J., Parmacek M.S., et al. SM22alpha promoter targets gene expression to vascular smooth muscle cells in vitro and in vivo. Mol Med. 6:2000;983-991.
6. Laitinen M., Mäkinen K., Manninen H., Matsi P., Kossila M., Agrawal R.S., et al. Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia. Hum Gene Ther. 9:1998;1481-1486.
7. Ribourtout E., Desfaits A.C., Salazkin I., Raymond J. Ex vivo gene therapy with adenovirus-mediated transforming growth factor beta1 expression for endovascular treatment of aneurysm: results in a canine bilateral aneurysm model. J Vasc Surg. 38:2003;576-583.
8. Schneider D.B., Sassani A.B., Vassalli G., Driscoll R.M., Dichek D.A. Adventitial delivery minimizes the proinflammatory effects of adenoviral vectors. J Vasc Surg. 29:1999;543-550.
9. Richter M., Iwata A., Nyhuis J., Nitta Y., Miller A.D., Halbert C.L., et al. Adeno-associated virus vector transduction of vascular smooth muscle cells in vivo. Physiol Genomic. 2:2000;117-127.
10. Dishart K.L., Denby L., George S.J., Nicklin S.A., Yendluri S., Tuerk M.J., et al. Third-generation lentivirus vectors efficiently transduce and phenotypically modify vascular cells: implications for gene therapy. J Mol Cell Cardiol. 35:2003;739-748.
11. Curran M.A., Kaiser S.M., Achacoso P.L., Nolan G.P. Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors. Mol Ther. 1:2000;31-38.
12. Sauter S.L., Gasmi M., Dubensky T.W. Jr. A highly efficient gene delivery system derived from feline immunodeficiency virus (FIV). Method Mol Med. 76:2003;405-432.
13. Lehtolainen P., Takeya M., Ylä-Herttuala S. Retrovirus-mediated, stable scavenger-receptor gene transfer leads to functional endocytotic receptor expression, foam cell formation, and increased susceptibility to apoptosis in rabbit aortic smooth muscle cells. Arterioscler Thromb Vasc Biol. 20:2000;52-60.
14. Laitinen M., Pakkanen T., Donetti E., Baetta R., Luoma J., Lehtolainen P., et al. Gene transfer into the carotid artery using an adventitial collar: comparison of the effectiveness of the plasmid-liposome complexes, retroviruses, pseudotyped retroviruses, and adenoviruses. Hum Gene Ther. 8:1997;1645-1650.
15. Price J., Turner D., Cepko C. Lineage analysis in the vertebrate nervous system by retrovirus-mediated gene transfer. Proc Natl Acad Sci USA. 84:1987;156-160.
16. Kalnins A., Otto K., Rüther U., Müller-Hill B. Sequence of the lacZ gene of Escherichia coli. EMBO J. 2:1983;593-597.
17. Burns J.C., Friedmann T., Driever W., Burrascano M., Yee J.K. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA. 90:1993;8033-8037.
18. Poeschla E.M., Wong-Staal F., Looney D.J. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat Med. 4:1998;354-357.
19. Turunen M.P., Hiltunen M.O., Ruponen M., Virkamäki L., Szoka F.C.J., Urtti A., et al. Efficient adventitial gene delivery to rabbit carotid artery with cationic polymer-plasmid complexes. Gene Ther. 6:1999;6-11.
20. Ylä-Herttuala S., Rosenfeld M.E., Parthasarathy S., Glass C.K., Sigal E., Witztum J.L., et al. Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesions. Proc Natl Acad Sci USA. 87:1990;6959-6963.
21. White S.J., Newby A.C. Gene therapy for all aspects of vein-graft disease. J Card Surg. 17:2002;549-555.
22. Hughes M., Vassilakos A., Andrews D.W., Hortelano G., Belmont J.W., Chang P.L. Delivery of a secretable adenosine deaminase through microcapsules - a novel approach to somatic gene therapy. Hum Gene Ther. 5:1994;1445-1455.
23. Plautz G., Nabel E.G., Nabel G.J. Introduction of vascular smooth muscle cells expressing recombinant genes in vivo. Circulation. 83:1991;578-583.
24. Pakkanen T.M., Laitinen M., Hippeläinen M., Hiltunen M.O., Alhava E., Ylä-Herttuala S. Periadventitial lacZ gene transfer to pig carotid arteries using a biodegradable collagen collar or a wrap of collagen sheet with adenoviruses and plasmid-liposome complexes. J Gene Med. 2:2000;52-60.
25. Osborne W.R., Ramesh N., Lau S., Clowes M.M., Dale D.C., Clowes A.W. Gene therapy for long-term expression of erythropoietin in rats. Proc Natl Acad Sci USA. 92:1995;8055-8058.
26. Yamada N., Shimano H., Yazaki Y. Role of apolipoprotein E in lipoprotein metabolism and in the process of atherosclerosis. J Atheroscler Thromb. 2: (Suppl 1):1995;S29-S33.
27. Mahley R.W., Huang Y. Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. Curr Opin Lipidol. 10:1999;207-217.
28. Ji Z.S., Fazio S., Lee Y.L., Mahley R.W. Secretion-capture role for apolipoprotein E in remnant lipoprotein metabolism involving cell surface heparin sulfate proteoglycans. J Biol Chem. 269:1994;2764-2772.
29. Bellosta S., Mahley R.W., Sanan D.A., Murata J., Newland D.L., Taylor J.M., et al. Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J Clin Invest. 96:1995;2170-2179.
30. Tsukamoto K., Tangirala R., Chun S.H., Pure E., Rader D.J. Rapid regression of atherosclerosis induced by liver-directed gene transfer of ApoE in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 19:1999;2162-2170.
31. Yamada N., Shimano H., Mokuno H., Ishibashi S., Gotohda T., Kawakami M., et al. Increased clearance of plasma cholesterol after injection of apolipoprotein E into Watanabe heritable hyperlipidemic rabbits. Proc Natl Acad Sci USA. 86:1989;665-669.
32. Yamada N., Inoue I., Kawamura M., Harada K., Watanabe Y., Shimano H., et al. Apolipoprotein E prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. J Clin Invest. 89:1992;706-711.
33. Shimano H., Ohsuga J., Shimada M., Namba Y., Gotoda T., Harada K., et al. Inhibition of diet-induced atheroma formation in transgenic mice expressing apolipoprotein E in the arterial wall. J Clin Invest. 95:1995;469-476.
34. Woollett L.A., Osono Y., Herz J., Dietschy J.M. Apolipoprotein E competitively inhibits receptor-dependent low density lipoprotein uptake by the liver but has no effect on cholesterol absorption or synthesis in the mouse. Proc Natl Acad Sci USA. 92:1995;12500-12504.
35. Fan J., Ji Z.S., Huang Y., de Silva H., Sanan D., Mahley R.W., et al. Increased expression of apolipoprotein E in transgenic rabbits results in reduced levels of very low density lipoproteins and an accumulation of low density lipoproteins in plasma. J Clin Invest. 101:1998;2151-2164.
36. Huang Y., Ji Z.S., Brecht W.J., Rall S.C. Jr, Taylor J.M., Mahley R.W. Overexpression of apolipoprotein E3 in transgenic rabbits causes combined hyperlipidemia by stimulating hepatic VLDL production and impairing VLDL lipolysis. Arterioscler Thromb Vasc Biol. 19:1999;2952-2959.
37. Tsukamoto K., Tangirala R.K., Chun S., Usher D., Pure E., Rader D.J. Hepatic expression of apolipoprotein E inhibits progression of atherosclerosis without reducing cholesterol levels in LDL receptor-deficient mice. Mol Ther. 1:2000;189-194.
38. Tangirala R.K., Pratico D., FitzGerald G.A., Chun S., Tsukamoto K., Maugeais C., et al. Reduction of isoprostanes and regression of advanced atherosclerosis by apolipoprotein E. J Biol Chem. 276:2001;261-266.
39. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., McCormack M.P., Wulffraat N., Leboulch P., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 302:2003;415-419.
40. Blömer U., Naldini L., Kafri T., Trono D., Verma I.M., Gage F.H. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol. 71:1997;6641-6649.
41. Kafri T., Blömer U., Peterson D.A., Gage F.H., Verma I.M. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet. 17:1997;314-317.
42. Gerolami R., Uch R., Jordier F., Chapel S., Bagnis C., Brechot C., et al. Gene transfer to hepatocellular carcinoma: transduction efficacy and transgene expression kinetics by using retroviral and lentiviral vectors. Cancer Gene Ther. 7:2000;1286-1292.
43. Indraccolo S., Habeler W., Tisato V., Stievano L., Piovan E., Tosello V., et al. Gene transfer in ovarian cancer cells: a comparison between retroviral and lentiviral vectors. Cancer Res. 62:2002;6099-6107.
44. Pannell D., Ellis J. Silencing of gene expression: implications for design of retrovirus vectors. Rev Med Virol. 11:2001;205-217.
45. Loser P., Jennings G.S., Strauss M., Sandig V. Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: involvement of NFkappaB. J Virol. 72:1998;180-190.
46. Johansen J., Rosenblad C., Andsberg K., Moller A., Lundberg C., Bjorlund A., et al. Evaluation of Tet-on system to avoid transgene down-regulation in ex vivo gene transfer to the CNS. Gene Ther. 9:2002;1291-1301.
47. Koponen J.K., Kankkonen H., Kannasto J., Wirth T., Hillen W., Bujard H., et al. Doxycycline-regulated lentiviral vector system with a novel reverse transactivator rtTA2(S)-M2 shows a tight control of gene expression in vitro and in vivo. Gene Ther. 10:2003;459-466.